Codon adds Roche Venture’s Mutz to team to capitalize therapeutic, synthetic bio start-ups

After seven years of making angel investments with founder and former CMEA Managing Director Karl Handelsman as its sole LP, San Francisco-based VC Codon Capital has brought Mitchell Mutz on board to ramp up early stage investments and company creation.

Mutz was most recently senior investment director at Roche Venture Fund, where Handelsman serves as a senior adviser. The duo has co-invested in multiple therapeutics companies, including protein play Good Therapeutics Inc. and cancer company Kumquat Biosciences Inc. ...